Dashboard
Manage Tickers

FHTX Foghorn Therapeutics Inc.

Nasdaq foghorntx.com


$ 4.24 $ -0.20 (-4.54 %)    

Monday, 03-Nov-2025 15:59:51 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 621.94 $ 0.00 (0 %)
DIA $ 468.86 $ 0.00 (0 %)
SPY $ 674.67 $ 0.00 (0 %)
TLT $ 89.96 $ 0.00 (0 %)
GLD $ 366.88 $ 0.00 (0 %)
$ 4.21
$ 4.40
$ 4.20 x 15
$ 4.40 x 51
-- - --
$ 2.94 - $ 9.70
236,122
na
237.99M
$ 1.61
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-04-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-06-2024 03-31-2024 10-Q
7 03-07-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-04-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-10-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-18-2021 12-31-2020 10-K
20 12-04-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

foghorn-therapeutics-to-present-updates-for-selective-arid1b-selective-cbp-and-selective-ep300-degrader-programs-during-foghorn-hosted-virtual-investor-event
Foghorn Therapeutics To Present Updates Fo...
10/30/2025 11:37:57

- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and...

foghorn-therapeutics-unveils-significant-arid1b-degrader-advances-plans-virtual-investor-event-for-pipeline-updates
Foghorn Therapeutics Unveils Significant A...
10/16/2025 11:04:52

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
08/11/2025 21:06:28

foghorn-therapeutics-q2-eps-028-beats-033-estimate-sales-7557m-beat-6498m-estimate
Foghorn Therapeutics Q2 EPS $(0.28) Beats ...
08/05/2025 11:37:53

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of ...

flagship-pioneering-launches-terrana-biosciences-with-50m-to-advance-rna-based-agtech-platform-for-climate-resilient-high-yield-crops
Flagship Pioneering Launches Terrana Biosc...
07/01/2025 10:33:23

jmp-securities-reiterates-market-outperform-on-foghorn-therapeutics-maintains-9-price-target
JMP Securities Reiterates Market Outperfor...
05/15/2025 13:48:54

JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform and maintains ...

foghorn-therapeutics-q1-eps-030-beats-031-estimate-sales-595m-beat-582m-estimate
Foghorn Therapeutics Q1 EPS $(0.30) Beats ...
05/14/2025 11:10:30

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of ...

jmp-securities-reiterates-market-outperform-on-foghorn-therapeutics-maintains-9-price-target
JMP Securities Reiterates Market Outperfor...
04/30/2025 14:50:54

JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform and maintains ...

hc-wainwright--co-reiterates-buy-on-foghorn-therapeutics-maintains-13-price-target
HC Wainwright & Co. Reiterates Buy on Fogh...
04/30/2025 10:38:57

HC Wainwright & Co. analyst Andres Maldonado reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $13 ...

foghorn-therapeutics-presents-new-data-on-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-and-selective-ep300-degrader-programs
Foghorn Therapeutics Presents New Data On ...
04/28/2025 20:06:32

FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as th...

this-paypal-analyst-begins-coverage-on-a-bearish-note-here-are-top-5-initiations-for-wednesday
This PayPal Analyst Begins Coverage On A B...
04/23/2025 13:19:39

jmp-securities-initiates-coverage-on-foghorn-therapeutics-with-market-outperform-rating-announces-price-target-of-9
JMP Securities Initiates Coverage On Fogho...
04/23/2025 11:36:39

JMP Securities analyst Silvan Tuerkcan initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform rat...

why-pvh-shares-are-trading-higher-by-around-15-here-are-20-stocks-moving-premarket
Why PVH Shares Are Trading Higher By Aroun...
04/01/2025 09:29:54

foghorn-therapeutics-will-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-and-ep300-degrader-programs-at-2025-aacr-meeting-in-chicago-april-24-20-2025
Foghorn Therapeutics Will Present New Prec...
03/25/2025 20:37:29

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology c...

hc-wainwright--co-reiterates-buy-on-foghorn-therapeutics-maintains-13-price-target
HC Wainwright & Co. Reiterates Buy on Fogh...
03/07/2025 12:10:59

HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $13 price...

foghorn-therapeutics-fy-2024-gaap-eps-158-beats-161-estimate-sales-22602m-miss-30713m-estimate
Foghorn Therapeutics FY 2024 GAAP EPS $(1....
03/06/2025 21:14:09

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(1.58) per share which beat the analyst consensus estimate of ...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
02/10/2025 21:05:43

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
02/04/2025 12:05:51

this-worthington-enterprises-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday
This Worthington Enterprises Analyst Begin...
01/30/2025 14:15:24

b-riley-securities-initiates-coverage-on-foghorn-therapeutics-with-buy-rating-announces-price-target-of-10
B. Riley Securities Initiates Coverage On ...
01/30/2025 10:58:35

B. Riley Securities analyst Kalpit Patel initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and anno...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION